Evidence map›Paper›PMID 11437413›Full record

ArticleBritish journal of cancer2001

Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines.

D Uchida, H Kawamata, K Nakashiro, F Omotehara, S Hino, M O Hoque, N M Begum, H Yoshida, M Sato, T Fujimori

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

D UchidaSecond Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, 3-18-15 Kuramoto, Tokushima, 770-8504, Japan.
H Kawamata
K Nakashiro
F Omotehara
S Hino
M O Hoque
N M Begum
H Yoshida
M Sato
T Fujimori
Tokushima University · JPDokkyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoids inhibit the proliferation of several types of tumour cells, and are used for patients with several malignant tumours. In this study, we examined the effect of retinoic acids (RAs) on the invasive potentials of the oral squamous cell carcinoma (SCC) cells, BHY and HNt. BHY cells expressed all of retinoid nuclear receptors (RARalpha, beta, gamma, and RXRalpha) and cytoplasmic retinoic acid binding proteins (CRABP1 and CRABP2). HNt cells lacked the expression of RARbeta, but expressed other nuclear receptors and CRABPs. All-trans retinoic acid (ATRA) and 13-cis retinoic acid (13-cisRA) (10(-6)and 10(-7)M) inhibited the growth of the cells, but low-dose ATRA and 13-cisRA (10(-8)M) marginally affected the growth of the cells. Surprisingly, low-dose RAs enhanced the activity of tissue-type plasminogen activator (tPA), and activated pro-matrix metalloproteinases (proMMP2 and proMMP9). Activation of proMMP2 and proMMP9 was inhibited by aprotinin, a serine-proteinase, tPA inhibitor. Furthermore, low-dose RAs enhanced the in vitro invasiveness of BHY cells. These results indicate that low-dose RAs enhances the in vitro invasiveness of oral SCC cells via an activation of proMMP2 and proMMP9 probably mediated by the induction of tPA.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellCell DivisionCollagenasesDose-Response Relationship, DrugEnzyme ActivationEnzyme PrecursorsGelatinasesHumansIsotretinoinMatrix Metalloproteinase 9Matrix Metalloproteinases, Membrane-AssociatedMetalloendopeptidasesMouth NeoplasmsNeoplasm InvasivenessReceptors, Retinoic AcidAntineoplastic AgentsCollagenasesEnzyme PrecursorsGelatinasesIsotretinoinMatrix Metalloproteinase 9Matrix Metalloproteinases, Membrane-AssociatedMetalloendopeptidasesprogelatinasepro-matrix metalloproteinase 9Receptors, Retinoic Acidretinoic acid binding protein I, cellularretinoic acid binding protein II, cellularTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Tissue Plasminogen ActivatorTretinoinUrokinase-Type Plasminogen Activator

Identifiers

PMID11437413
PMCPMC2363904
OpenAlexW2085036524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.